Drug Profile
Research programme: monoclonal antibody-based therapeutics - Compugen/Medarex
Alternative Names: CGEN-837Latest Information Update: 25 Sep 2013
Price :
$50
*
At a glance
- Originator Compugen; Medarex
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 25 Sep 2013 Discontinued for Autoimmune disorders in Israel and USA (Parenteral)
- 25 Sep 2013 Discontinued for Cancer in Israel and USA (Parenteral)
- 03 Sep 2009 This programme is in active development